Alkermes’ Orexin-2 Receptor Agonist for Narcolepsy Enters Phase 2 Trials
The phase 2 trial will evaluate the safety and efficacy of ALKS 2680, a novel orexin-2 receptor agonist, in patients with narcolepsy type 1.
The phase 2 trial will evaluate the safety and efficacy of ALKS 2680, a novel orexin-2 receptor agonist, in patients with narcolepsy type 1.
Wakix is the first Health Canada-approved treatment for children 6 years of age and older experiencing excessive daytime sleepiness or cataplexy symptoms associated with narcolepsy.
The men experienced serious skin reactions and mouth ulcers after taking drugs indicated for narcolepsy. They had been hoping for cognitive enhancement.
Jazz exited the fourth quarter with approximately 12,300 active Xywav patients, up from 12,050 in the previous quarter.
Read MoreAxsome Therapeutics prepares to read out a phase 3 trial for narcolepsy drug candidate AXS-12 and initiate a new pivotal trial for solriamfetol in shift work disorder this quarter.
Read MoreThe FDA has granted priority review to Harmony Biosciences’ supplemental New Drug Application for Wakix for treating excessive daytime sleepiness or cataplexy in children aged 6 and older with narcolepsy.
Read MoreAlkermes plans to initiate phase 2 trials for its orexin-2 receptor agonist, ALKS 2680, aimed at treating narcolepsy within the first half of the year.
Read MoreTakeda announced positive results from a phase 2b trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.
Read MoreSleep specialists share practical tips on choosing medications that treat narcolepsy symptoms, including excessive daytime sleepiness and cataplexy.
Read MoreHarmony Biosciences announced an increase in the usage of its narcolepsy drug Wakix (pitolisant) during the fourth quarter.
Read MoreAvadel Pharmaceuticals shared updates on the performance and reception of its new narcolepsy medication, Lumryz, a once-at-bedtime extended-release sodium oxybate medication that has been on the market since June 2023.
Read MoreAxsome Therapeutics details anticipated milestones for investigational drugs for narcolepsy and excessive daytime sleepiness associated with shift work disorder.
Read MoreThe ongoing Adderall shortage is creating widespread difficulties for narcolepsy patients, disrupting treatment and daily life across the US.
Read MoreNew research suggests it’s possible to interact and communicate with people during sleep, potentially across various sleep stages.
Read MoreIn a letter to shareholders, the CEO of Swiss clinical-stage biopharmaceutical company NLS Pharmaceutics Ltd recapped the company’s progress and pitfalls for 2023.
Read MoreThe option agreement grants NLS Pharmaceutics the exclusive option to in-license all of Aexon Labs’ assets for the potential treatment of narcolepsy and other neurodegenerative disorders.
Read MoreJazz Pharmaceuticals is pausing its phase 1 clinical trial investigating JZP441, an oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy and other sleep disorders, after reports of adverse effects.
Read MoreNLS Pharmaceutics is exploring strategic alternatives, including the out-licensing of its key asset Mazindol, to maximize shareholder value.
Read More